NuScale is in a deep, sustained downtrend, with the stock price falling 84.1% over the past year and currently trading at $8.09, just 14.1% above its 52-week low of $7.21. The price sits near the bottom of its 52-week range (7.21–57.42), indicating persistent selling pressure and a lack of buyer conviction. This positioning near the low suggests the stock is deeply out of favor, but also raises the risk of further downside if support fails. Short-term momentum remains decisively negative, with the stock down 20.8% over the past month and 32.4% over the past three months. The 1-month decline of 20.8% is accelerating relative to the 3-month decline, signaling intensifying bearish sentiment. The stock's beta of 2.252 indicates it is more than twice as volatile as the S&P 500, amplifying both downside risk and potential upside in a reversal. Key support lies at the 52-week low of $7.21; a breakdown below this level could trigger further selling toward single-digit lows. Resistance is at the 52-week high of $57.42, though near-term resistance is likely around $10–$12, where the stock traded in early July. The high beta and extreme volatility make this a high-risk position requiring strict risk management.

NuScale's revenue trajectory is severely declining, with Q1 2026 revenue of just $565,000, down 95.8% year-over-year from $13.4 million in Q1 2025. The multi-quarter trend shows a collapse from $34.2 million in Q4 2024 to near-zero levels, reflecting failed commercialization and project cancellations. The company is pre-revenue in a commercial sense, with no meaningful product sales, making the investment case entirely dependent on future regulatory approvals and customer adoption. The company is deeply unprofitable, reporting a net loss of $44.0 million in Q1 2026, with a gross margin of -43.2% (negative gross profit of $244,000). Operating margin worsened to -101.8%, indicating that operating expenses far exceed revenue. While net losses have narrowed from $273.3 million in Q3 2025 (which included a large impairment), the trajectory toward profitability remains distant, with negative net margins of -77.9% in Q1 2026. NuScale has zero debt (debt-to-equity ratio of 0) and a current ratio of 4.3, indicating ample short-term liquidity. However, free cash flow was -$316.2 million in Q1 2026, and trailing twelve-month free cash flow was -$753.5 million, highlighting heavy cash burn. The company relies on equity financing (common stock issued $37.8 million in Q1 2026) to fund operations, and with a negative ROE of -30.4%, it is destroying shareholder value. Cash at end of Q1 2026 was $346.2 million, providing a runway of roughly one year at the current burn rate.